NEW YORK (360Dx) – Angle said this week that the first patient has been enrolled in its ANG-002 clinical study for metastatic breast cancer. The study will support the company's planned application to the US Food and Drug Administration to receive Class II clearance for a product for harvesting intact circulating tumor cells from patient blood for subsequent analysis. The clinical study involves recruitment of 200 metastatic breast cancer patients and 200 healthy volunteers enrolled at leading US cancer centers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.